Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | cytochrome P450, family 1, subfamily A, polypeptide 2 | Starlite/ChEMBL | No references |
Homo sapiens | TAR DNA binding protein | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | Cytochrome P450 family protein | cytochrome P450, family 1, subfamily A, polypeptide 2 | 516 aa | 470 aa | 26.2 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0048 | 0.2961 | 0.5532 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0048 | 0.2961 | 0.5532 |
Leishmania major | hypothetical protein, conserved | 0.0028 | 0.1286 | 0.5 |
Plasmodium vivax | ataxin-2 like protein, putative | 0.0028 | 0.1286 | 0.5 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0028 | 0.1286 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.5353 | 1 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0048 | 0.2961 | 0.5532 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.5353 | 1 |
Brugia malayi | hypothetical protein | 0.0028 | 0.1286 | 0.0866 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0048 | 0.2961 | 0.5532 |
Brugia malayi | RNA binding protein | 0.0076 | 0.5353 | 0.5129 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0048 | 0.2961 | 0.5532 |
Loa Loa (eye worm) | TAR-binding protein | 0.0076 | 0.5353 | 0.4667 |
Echinococcus multilocularis | tar DNA binding protein | 0.0076 | 0.5353 | 1 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0048 | 0.2961 | 0.5532 |
Loa Loa (eye worm) | transcription factor SMAD2 | 0.0132 | 1 | 1 |
Loa Loa (eye worm) | RNA binding protein | 0.0076 | 0.5353 | 0.4667 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0028 | 0.1286 | 0.5 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0028 | 0.1286 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.5353 | 1 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0048 | 0.2961 | 0.5532 |
Trypanosoma brucei | PAB1-binding protein , putative | 0.0028 | 0.1286 | 0.5 |
Brugia malayi | GTP-binding regulatory protein Gs alpha-S chain, putative | 0.0048 | 0.2961 | 0.2622 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.5353 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.5353 | 1 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0076 | 0.5353 | 0.4667 |
Loa Loa (eye worm) | MH2 domain-containing protein | 0.0132 | 1 | 1 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0076 | 0.5353 | 0.5129 |
Brugia malayi | TAR-binding protein | 0.0076 | 0.5353 | 0.5129 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0028 | 0.1286 | 0.5 |
Echinococcus granulosus | tar DNA binding protein | 0.0076 | 0.5353 | 1 |
Toxoplasma gondii | LsmAD domain-containing protein | 0.0028 | 0.1286 | 0.5 |
Loa Loa (eye worm) | GTP-binding regulatory protein Gs alpha-S chain | 0.0048 | 0.2961 | 0.1923 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
AC50 (functional) | PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp3a4 Compounds with AC50 equal or less than 10 uM are considered active | ChEMBL. | No reference | |
AC50 (functional) | PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2d6 Compounds with AC50 equal or less than 10 uM are considered active | ChEMBL. | No reference | |
AC50 (functional) | PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c9 Compounds with AC50 equal or less than 10 uM are considered active | ChEMBL. | No reference | |
AC50 (functional) | PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c19 Compounds with AC50 equal or less than 10 uM are considered active | ChEMBL. | No reference | |
AC50 (functional) | = 10 uM | PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp1a2 Compounds with AC50 equal or less than 10 uM are considered active | ChEMBL. | No reference |
Potency (functional) | 5.6234 uM | PubChem BioAssay. qHTS of TDP-43 Inhibitors. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 11.6891 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 25.929 uM | PUBCHEM_BIOASSAY: Nrf2 qHTS screen for inhibitors. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493153, AID493163, AID504648] | ChEMBL. | No reference |
Potency (functional) | 50.1187 uM | PubChem BioAssay. qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 100 uM | PUBCHEM_BIOASSAY: HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.